Allotera Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 45

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $150M

  • Investors
  • 14

Allotera Therapeutics General Information

Description

Developer of allogeneic CAR-T cell therapies designed to treat hematological cancers. The company offers off-the-shelf CAR-T cell therapies, gene-editing technology, and advanced cell manufacturing capabilities, enabling healthcare providers and patients with hematological malignancies to access targeted cell therapies with improved availability and treatment potential.

Contact Information

Formerly Known As
Wugen
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4260 Forest Park Avenue
  • Suite 100
  • Saint Louis, MO 63108
  • United States
+1 (636)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 4260 Forest Park Avenue
  • Suite 100
  • Saint Louis, MO 63108
  • United States
+1 (636)

Allotera Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allotera Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 08-Jul-2026 $150M Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 16-Dec-2022 Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 13-Apr-2020 $36M $36M Completed Clinical Trials - Phase 2
To view Allotera Therapeutics’s complete valuation and funding history, request access »

Allotera Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-1
Series C
Series B 20,938,376 $0.000010 $0.62 $7.75 $7.75 1x $7.75 12.89%
Series A 11,673,206 $0.000010 $0.28 $3.56 $3.56 1x $3.56 7.19%
To view Allotera Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Allotera Therapeutics Patents

Allotera Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026107398-A2 Improved methods of making genome-edited immune effector cells Pending 15-Nov-2024
WO-2026107398-A3 Improved methods of making genome-edited immune effector cells Pending 15-Nov-2024
US-20240189355-A1 Hypoimmunogenic cells having targeted modifications in mhc class-i genes and methods of use Pending 14-Nov-2022
WO-2024107742-A1 Hypoimmunogenic cells having targeted modifications in mhc class-i genes and methods of use Inactive 14-Nov-2022
AU-2023371649-A1 Generation of cd3 expressing immune cells for use in conjunction with cd3 binding bispecific targeting agents Pending 04-Nov-2022 A61K40/15
To view Allotera Therapeutics’s complete patent history, request access »

Allotera Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allotera Therapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Therapy Acceleration Program (TAP) Not-For-Profit Venture Capital Minority
Abingworth Venture Capital Minority
Aisling Capital Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
Alpha Wave Global Growth/Expansion Minority
You’re viewing 5 of 14 investors. Get the full list »

Allotera Therapeutics FAQs

  • When was Allotera Therapeutics founded?

    Allotera Therapeutics was founded in 2018.

  • Where is Allotera Therapeutics headquartered?

    Allotera Therapeutics is headquartered in Saint Louis, MO.

  • What is the size of Allotera Therapeutics?

    Allotera Therapeutics has 45 total employees.

  • What industry is Allotera Therapeutics in?

    Allotera Therapeutics’s primary industry is Drug Discovery.

  • Is Allotera Therapeutics a private or public company?

    Allotera Therapeutics is a Private company.

  • What is the current valuation of Allotera Therapeutics?

    The current valuation of Allotera Therapeutics is .

  • What is Allotera Therapeutics’s current revenue?

    The current revenue for Allotera Therapeutics is .

  • How much funding has Allotera Therapeutics raised over time?

    Allotera Therapeutics has raised $358M.

  • Who are Allotera Therapeutics’s investors?

    Therapy Acceleration Program (TAP), Abingworth, Aisling Capital, Alexandria Venture Investments, and Alpha Wave Global are 5 of 14 investors who have invested in Allotera Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process